Summary The latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.
Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.
Report Highlights The Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 6, 1, 5, 9, 6 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Apr 2021
Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, and Eli Lilly. The global blood cancer drugs market is expected to grow from $20.66 billion in 2020 to $21.6 billion in 2021 at a compound annual growth rate (CAGR) of 4.5%. The growth is mainly due to the companies rearranging...
The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies....
The oncology information systems market is projected to reach USD 9.5 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 7.4% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of cancer cases, and growing public and private investments, funding, and grants...
Gliosarcoma - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2020, provides an overview of the Gliosarcoma (Oncology) pipeline landscape. Gliosarcoma is a type of brain tumor that originates from glial cells....
442 pages •
By The Business Research Company
• Nov 2020
Oncology Drugs Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market. Description: Where is the largest and fastest growing market for the oncology...
The global cold plasma equipment market is expected to reach US$ 308.87 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.6% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing...
Aryl Hydrocarbon Receptor - Pipeline Review, H2 2020 Summary Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes....
Oligodendroglioma - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2020, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape. Oligodendroglioma is a type of glioma (primary...